Search Results
You are looking at 1 - 8 of 8 items for
- Author: C Ball x
- Refine by access: All content x
Search for other papers by J. M. C. Connell in
Google Scholar
PubMed
Search for other papers by C. J. Kenyon in
Google Scholar
PubMed
Search for other papers by S. G. Ball in
Google Scholar
PubMed
Search for other papers by D. L. Davies in
Google Scholar
PubMed
Search for other papers by R. Fraser in
Google Scholar
PubMed
ABSTRACT
The effect of dopamine (1 μg/kg per min) on corticosteroid response to ACTH (0·1, 1 and 10 ng/kg per min) was compared with that of a placebo in sodium-replete (150 mmol/day) and -deplete (10 mmol/day) normal man. Dopamine had no effect on aldosterone, cortisol or corticosterone responses in either dietary phase, but increased deoxycorticosterone (897·0 ± 126·4 (s.e.m.) vs 590·0 ±84·3 pmol/l, normal Na+; 1264·2 ±84·3 vs 764·5 ±84·3 pmol/l, low Na+) and deoxycortisol (6·033 ± 0·583 vs 5·048±0·680 nmol/l, normal Na+; 5·112 ± 0·600 vs 4·130± 0·367 nmol/l, low Na+) levels during ACTH administration (all P <0·01). Deoxycorticosterone and corticosterone responses to ACTH were greater during sodium depletion than repletion (both P <0·01).
Dopamine therefore increased 11-deoxycorticosteroid concentrations during ACTH-stimulated steroidogenesis. This may reflect action of dopamine to increase extra-adrenal formation of 11-deoxycorticosteroids.
J. Endocr. (1986) 109, 339–344
Search for other papers by V.K.K. Chatterjee in
Google Scholar
PubMed
Search for other papers by J.A. Ball in
Google Scholar
PubMed
Search for other papers by C. Proby in
Google Scholar
PubMed
Search for other papers by J.M. Burrin in
Google Scholar
PubMed
Search for other papers by S.R. Bloom in
Google Scholar
PubMed
ABSTRACT
In five healthy normal male volunteers, pretreatment with the cholinergic muscarinic antagonist pirenzepine (30 mg i.v.) almost abolished the growth hormone (GH) response to a maximal dose (120 μg i.v.) of growth hormone-releasing hormone (GHRH) (GH response at 40 min 5.6 ± 1.3 mU/l with GHRH and pirenzepine vs 40.8 ± 5.3 mU/l with GHRH alone, P <0.02). Concomitant i.v. infusion of galanin (40 pmol/kg/min) with pirenzepine not only restored but significantly potentiated the GH response to GHRH (GH at 40 min 72.2 ± 10.5 mU/l, P <0.001 vs GHRH and pirenzepine, P <0.02 vs GHRH alone). Previous studies have proposed that cholinergic pathways control GH release via samatostatin and this study suggests that galanin may act by modulating hypothalamic somatostatinergic tone either directly or, possibly, by facilitating cholinergic neurotransmission.
Search for other papers by C Aurich in
Google Scholar
PubMed
Search for other papers by P F Daels in
Google Scholar
PubMed
Search for other papers by B A Ball in
Google Scholar
PubMed
Search for other papers by J E Aurich in
Google Scholar
PubMed
Abstract
The aim of the present study was to investigate the role of ovarian steroids in the opioid regulation of LH and prolactin release in mares. Effects of the opioid antagonist naloxone on LH and prolactin secretion were determined in ovariectomized pony mares. The animals were pretreated with either progesterone (500 μg kg−1) or oestradiol benzoate (10 μg kg−1) for 8 days and subsequently with a combination of progesterone and oestradiol for an additional 8 days. Naloxone administration (0·5 mg kg−1 i.v.) resulted in a significant release of LH as well as prolactin in mares after pretreatment with either oestradiol benzoate or progesterone plus oestradiol benzoate (P<0·05). No significant changes in LH and prolactin secretion were detected in progesterone-treated and non-steroid-treated ovariectomized mares. These results indicate that a prolonged oestrogen influence activates the opioid inhibition of LH and prolactin release in mares. In contrast to other species, progesterone alone does not activate a tonic opioid inhibition of LH and prolactin secretion, but modulates the effect of oestrogens. The opioid systems therefore seem to be regulated by a sequence of different steroid environments, as found during the oestrous cycle. The parallel increases in prolactin and LH secretion in mares may indicate a common regulatory pathway for these two hormones.
Journal of Endocrinology (1995) 147, 195–202
Search for other papers by BS Shepherd in
Google Scholar
PubMed
Search for other papers by T Sakamoto in
Google Scholar
PubMed
Search for other papers by S Hyodo in
Google Scholar
PubMed
Search for other papers by RS Nishioka in
Google Scholar
PubMed
Search for other papers by C Ball in
Google Scholar
PubMed
Search for other papers by HA Bern in
Google Scholar
PubMed
Search for other papers by EG Grau in
Google Scholar
PubMed
We examined the effects of environmental salinity on circulating levels of the two prolactins (tPRL177 and tPRL188) and levels of pituitary tPRL177 and tPRL188 mRNA in the euryhaline tilapia, Oreochromis mossambicus. Fish were sham-operated or hypophysectomized and the rostral pars distalis (RPD) autotransplanted onto the optic nerve. Following post-operative recovery in (1/4) seawater, tilapia were transferred to fresh water (FW), (1/4) seawater (SW) or SW. Serum tPRL177 and tPRL188 levels in sham-operated and RPD-autotransplanted fish were highest in FW and decreased as salinity was increased. tPRL177 and tPRL188 mRNA levels in RPD implants as well as in pituitaries from the sham-operated fish were also highest in FW and decreased with increasing salinity. Serum osmolality increased with salinity, with the highest levels occurring in the seawater groups. We conclude that some plasma factor (probably plasma osmolality), in the absence of hypothalamic innervation, exerts a direct regulatory action on prolactin release and gene expression in the pituitary of O. mossambicus. This regulation is in accord with the actions of the two prolactins in the freshwater osmoregulation of the tilapia.
Search for other papers by J. M. C. Connell in
Google Scholar
PubMed
Search for other papers by G. Tonolo in
Google Scholar
PubMed
Search for other papers by D. L. Davies in
Google Scholar
PubMed
Search for other papers by J. Finlayson in
Google Scholar
PubMed
Search for other papers by S. G. Ball in
Google Scholar
PubMed
Search for other papers by G. Inglis in
Google Scholar
PubMed
Search for other papers by R. Fraser in
Google Scholar
PubMed
ABSTRACT
Infusion of dopamine is reported to reduce the response of aldosterone to infused angiotensin II in sodium-deplete but not sodium-replete man. Six normal male subjects were infused with angiotensin II in graded doses (2, 4 and 8 ng/kg per min) with or without dopamine (1·0 μg/kg per min) during both dietary sodium repletion and depletion. The responses of both aldosterone and 18-hydroxycorticosterone to infusion of angiotensin II appeared to be reduced by dopamine in sodium-deplete, but not sodium-replete, subjects. However, when the relationships between plasma concentrations of angiotensin II and corticosteroid were examined it was evident that plasma concentrations of angiotensin II were lower when dopamine was infused concurrently with the peptide (P<0·05).
In a second study, six sodium-deplete males were infused with angiotensin II at a constant rate (6 ng/kg per min) while dopamine (or placebo) was given in graded doses (0·5,1 and 5 μg/kg per min). Renal plasma flow was estimated from total body clearance of para-aminohippuric acid. Overall, angiotensin II concentrations were lower during dopamine infusion compared with those during infusion of placebo (63·2 ± 9·7 (s.e.m.) vs 92·3±6·4 pmol/l; P<0·01) and this was associated with a 40% increase in effective renal plasma flow (627 ± 68 vs 451 ± 15 ml/min; P < 0·05); there again appeared to be a reduced aldosterone response during combined angiotensin II/dopamine infusion compared with that during infusion of angiotensin II alone (1003 ± 404 vs 1225± 146 pmol/l; 0·05<P<0·1).
Dopamine appeared to increase the metabolic clearance of infused angiotensin II, possibly by altering blood flow through vascular beds, such as renal, which degrade the peptide. This may partly explain the effects of dopamine on the response of the adrenal to infusion of angiotensin II in sodium-deplete man; the physiological role of dopamine in the regulation of corticosteroidogenesis remains speculative.
J. Endocr. (1987) 113, 139–146
Search for other papers by K. P. McNatty in
Google Scholar
PubMed
Search for other papers by N. Hudson in
Google Scholar
PubMed
Search for other papers by M. Gibb in
Google Scholar
PubMed
Search for other papers by K. Ball in
Google Scholar
PubMed
Search for other papers by J. Fannin in
Google Scholar
PubMed
Search for other papers by L. Kieboom in
Google Scholar
PubMed
Search for other papers by D. C. Thurley in
Google Scholar
PubMed
ABSTRACT
The aim of the present study was to establish whether cyclic ovarian activity could be induced and then maintained in anoestrous Romney ewes by the long-term administration of regular intravenous pulses of LH (10 μg ovine LH i.v. once every 1 or 2 h for 29–91 days). The LH pulse regimen was designed to generate plasma profiles of LH that were comparable to those experienced during the luteal and follicular phases of the oestrous cycle.
The results showed that the LH treatments were capable of inducing cyclic ovarian activity, as assessed from the concentrations of progesterone in plasma, but that the treatments were inadequate for sustaining cyclic activity beyond two consecutive progestational phases. After 35–56 days of treatment, the plasma concentrations of FSH declined significantly (P <0·05) relative to those in the untreated animals. These data suggest that FSH supplementation as well as LH might be required for the long-term maintenance of cyclic ovarian activity in seasonally anoestrous ewes.
J. Endocr. (1984) 100, 67–73
Search for other papers by C J Corbin in
Google Scholar
PubMed
Search for other papers by E L Legacki in
Google Scholar
PubMed
Search for other papers by B A Ball in
Google Scholar
PubMed
Search for other papers by K E Scoggin in
Google Scholar
PubMed
Search for other papers by S D Stanley in
Google Scholar
PubMed
Search for other papers by A J Conley in
Google Scholar
PubMed
The 5α-reductase enzymes play an important role during male sexual differentiation, and in pregnant females, especially equine species where maintenance relies on 5α-reduced progesterone, 5α-dihydroprogesterone (DHP). Epididymis expresses 5α-reductases but was not studied elaborately in horses. Epididymis from younger and older postpubertal stallions was divided into caput, corpus and cauda and examined for 5α-reductase activity and expression of type 1 and 2 isoforms by quantitative real-time polymerase chain reaction (qPCR). Metabolism of progesterone and testosterone to DHP and dihydrotestosterone (DHT), respectively, by epididymal microsomal protein was examined by thin-layer chromatography and verified by liquid chromatography tandem mass spectrometry (LC-MS/MS). Relative inhibitory potencies of finasteride and dutasteride toward equine 5α-reductase activity were investigated. Pregnenolone was investigated as an additional potential substrate for 5α-reductase, suggested previously from in vivo studies in mares but never directly examined. No regional gradient of 5α-reductase expression was observed by either enzyme activity or transcript analysis. Results of PCR experiments suggested that type 1 isoform predominates in equine epididymis. Primers for the type 2 isoform were unable to amplify product from any samples examined. Progesterone and testosterone were readily reduced to DHP and DHT, and activity was effectively inhibited by both inhibitors. Using epididymis as an enzyme source, no experimental evidence was obtained supporting the notion that pregnenolone could be directly metabolized by equine 5α-reductases as has been suggested by previous investigators speculating on alternative metabolic pathways leading to DHP synthesis in placenta during equine pregnancies.
Search for other papers by A J Conley in
Google Scholar
PubMed
Search for other papers by E L Scholtz in
Google Scholar
PubMed
Search for other papers by E L Legacki in
Google Scholar
PubMed
Search for other papers by C J Corbin in
Google Scholar
PubMed
Search for other papers by H K Knych in
Google Scholar
PubMed
Search for other papers by G D Dujovne in
Google Scholar
PubMed
Search for other papers by B A Ball in
Google Scholar
PubMed
Search for other papers by B C Moeller in
Google Scholar
PubMed
Search for other papers by S D Stanley in
Google Scholar
PubMed
In vivo and in vitro evidence indicates that the bioactive, 5α-reduced progesterone metabolite, 5α-dihydroprogesterone (DHP) is synthesized in the placenta, supporting equine pregnancy, but its appearance in early pregnancy argues for other sites of synthesis also. It remains unknown if DHP circulates at relevant concentrations in cyclic mares and, if so, does synthesis involve the non-pregnant uterus? Jugular blood was drawn daily from cyclic mares (n = 5). Additionally, ovariectomized mares (OVX) and geldings were administered progesterone (300 mg) intramuscularly. Blood was drawn before and after treatment. Incubations of whole equine blood and hepatic microsomes with progesterone were also investigated for evidence of DHP synthesis. Sample analysis for progesterone, DHP and other steroids employed validated liquid chromatography–tandem mass spectrometry methods. Progesterone and DHP appeared a day (d) after ovulation in cyclic mares, was increased significantly by d3, peaking from d5 to 10 and decreased from d13 to 17. DHP was 55.5 ± 3.2% of progesterone concentrations throughout the cycle and was highly correlated with it. DHP was detected immediately after progesterone administration to OVX mares and geldings, maintaining a relatively constant ratio with progesterone (47.2 ± 2.9 and 51.2 ± 2.7%, respectively). DHP was barely detectable in whole blood and hepatic microsome incubations. We conclude that DHP is a physiologically relevant progestogen in cyclic, non-pregnant mares, likely stimulating the uterus, and that it is synthesized peripherally from luteal progesterone but not in the liver or blood. The presence of DHP in pregnant perissodactyla as well as proboscidean species suggests horses may be a valuable model for reproductive endocrinology in other exotic taxa.
